Results 291 to 300 of about 2,405,382 (374)

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami   +10 more
wiley   +1 more source

Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome

open access: yesArthritis &Rheumatology, EarlyView.
Objective Antiphospholipid syndrome (APS) is a thromboinflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)–positive patients using whole‐blood transcriptomics.
Amala Ambati   +13 more
wiley   +1 more source

Stearic acid-modified PSMA-targeting peptide-drug conjugate for long-acting prostate cancer therapy. [PDF]

open access: yesChem Sci
Qiu Z   +9 more
europepmc   +1 more source

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy